PRAX

Recent stories

• +8

  FDA granted Breakthrough Therapy Designation for ulixacaltamide.

  1 source·29/12, 13:06·sec.gov

• +8

  FDA agreement boosts elsunersen study prospects.

  1 source·11/12, 21:28·sec.gov

• +9

  Positive NDA progress and clinical trial results announced.

  1 source·08/12, 21:20·sec.gov

• 0

  10-Q form submitted!

  1 source·05/11, 14:15·sec.gov

• 0

  Routine financial results announcement.

  1 source·05/11, 14:11·sec.gov

• +6

  FDA grants Type B meeting regarding ulixacaltamide.

  1 source·21/10, 12:04·sec.gov

• +8

  Praxis raises $567 million in stock offering.

  1 source·20/10, 10:03·sec.gov

• +8

  Praxis announced positive results for ulixacaltamide study.

  1 source·16/10, 12:04·sec.gov

• +5

  Praxis terminates old sales agreement, initiates new one.

  1 source·05/09, 20:50·sec.gov

• +8

  Positive topline results from RADIANT study announced.

  1 source·04/08, 12:54·sec.gov